Eurofins: Predictable Growth At A Reasonable Price

Fernanda Galvez Jalil1.05K FollowersFollow5ShareSavePlay(9min)CommentsSummaryEurofins offers a stable, defensive growth profile with global scale in laboratory testing across healthcare, food, and biopharma segments.Organic growth has normalized post-COVID, with management targeting 6.5% annually and additional upside from acquisitions and capital returns.Valuation appears reasonable, supporting a potential 10–12% total return plus a 2% dividend yield, given the company’s stability and buyback activity.Key risks include reliance on acquisitions for growth and exposure to rising financing costs, though current debt maturities are well distributed. Morsa Images/DigitalVision via Getty Images Investment thesis Eurofins (ERFSF) might not be the type of company that immediately stands out, given its moderate growth. That said, I believe Eurofins offers a relatively predictable growth profile due to its stable business. If theThis article was written byFernanda Galvez Jalil1.05K FollowersFollowMy name is María Fernanda and I'm currently studying an MBA. My inspiration investors are Warren Buffett, Peter Lynch and Terry Smith, so I look for quality companies at a reasonable valuation. I believe that, in the long term, fundamentals are what drive the share price, so I look to predict what a business's earnings per share will do.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ERFSF over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.